CRBP Corbus Pharmaceuticals Holdings, Inc.

NASDAQ
$3.93

Corbus Pharmaceuticals Holdings, Inc. (CRBP) is confirmed to report earnings on November 10, 2026, before the market open. The consensus earnings estimate is a loss of $1.45 per share.

Corbus Pharmaceuticals Missed Consensus Estimates
Tuesday, November 10, 2026 · 8:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 10
Tuesday · 8:00 AM ET
Earnings Whisper
-
vs ($1.45)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $6.73

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Holdings Inc is a clinical stage biopharmaceutical company. The Company is focused on the development and commercialization of novel therapeutics to treat rare, life-threating inflammatory-fibrotic diseases.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.